Metrion Biosciences and LifeArc Announce Collaboration to Support LifeArc’s Neuroscience Programme – Technology Networks

Metrion Biosciences Limited (Metrion), the specialist ion channel CRO and drug discovery company, and LifeArc, the UK medical research charity previously known as MRC Technology, newly announced an extension of their existing partnership, to support LifeArcs neuroscience drug discovery programme.

Under the terms of the agreement Metrion will provide validated ion channel and electrophysiology-based assays and safety profiling services, and LifeArc will conduct medicinal chemistry aimed at identifying novel modulators of an undisclosed CNS ion channel target. In addition, Metrion will contribute translational research expertise to evaluate the activity of LifeArc compounds in human neuronal networks.

Metrion will provide translational assay support by applying its extensive background knowledge in ion channel research, microelectrode array (MEA) technology, and access to its CiPA-compliant cardiac safety assays.

Dr Andrew Southan, Chief Operating Officer, Metrion Biosciences, said: The Metrion team has a long history of developing, validating, and providing specialist ion channel assays to optimise and select development candidate molecules. We believe combining this with translational neuroscience and microelectrode array capability, as we are in this promising project with LifeArc, may be particularly successful in CNS research.

Justin Bryans, Executive Director, Drug Discovery, LifeArc, commented: LifeArc is committed to working with cutting edge organisations such as Metrion, capitalising on our combined expertise and capabilities to advance programmes addressing human health. Our previous experience in working with the team at Metrion has been excellent, and we look forward to continuing the relationship.

This article has been republished frommaterialsprovided by Metrion Biosciences. Note: material may have been edited for length and content. For further information, please contact the cited source.

Read more:
Metrion Biosciences and LifeArc Announce Collaboration to Support LifeArc's Neuroscience Programme - Technology Networks

IRICoR announces the appointment of Dr. Martin Godbout as Chairman of its Board of Directors and of Ms. Catherine … – Markets Insider

MONTREAL, July 31, 2017 /CNW Telbec/ - IRICoR (Institute for Research in Immunology and Cancer - Commercialization of Research) proudly announces the appointment of Dr. Martin Godbout, president of Hodran Consultants Inc., as the new Chairman of its Board of Directors and of Ms. Catherine Bouchard, Head of Research, Life Sciences at the Caisse de dpt et placement du Qubec, as a new Board member.

Dr. Godbout brings to IRICoR's Board a deep expertise in the health sciences sector. With his thorough knowledge of the field and his close to 30-year experience, he will greatly contribute to IRICoR's ongoing initiatives to attract and accelerate the development of promising innovative projects in oncology. Dr. Godbout started his professional career as President and CEO of Socit Innovatech Qubec, a technology-focused venture capital (VC) fund. He then served as Executive Vice-president of BioCapital, a biopharmaceutical VC firm, after which he founded Genome Canada, which he successfully led for more than 10 years as CEO. He was also a Board member of numerous biopharmaceutical companies, not-for-profit organizations involved in funding research and innovation and philanthropic organizations. He is currently Chair of the Board at Amorchem-I, BioContact, BioQubec and Genome Quebec, and a Board Member of various organizations, including the Fonds de recherche du Qubec Sant. Dr. Godbout holds a B.Sc. in Biochemistry and a Ph.D. in Physiology and Molecular Endocrinology from Universit Laval. He completed his post-doctoral training in Molecular Neurobiology at San Diego'sScripps Research Institute. Finally, Dr. Godbout is an Officer at the Order of Canada.

"We enthusiastically welcome Dr. Godbout to IRICoR's team. His diverse professional expertise both in the healthcare and business sectors, as well as his broad professional network will be critical to the success of IRICoR's ongoing strategic initiatives."Nadine Beauger, Chief Executive Officer - IRICoR

Dr. Godbout succeeds Johane Boucher-Champagne who was Chair of IRICoR's Board since 2011, after having been a member since 2009. IRICoR takes this opportunity to formally thank Mrs. Boucher-Champagne for having put her deep experience in the life science sector to the service of IRICoR. She has truly been a key resource for the organization through all those years.

"Through her deep knowledge of the pharmaceutical sector and her keen governance skills, Mrs. Boucher-Champagne skillfully managed to further IRICoR's initiatives, leading the organization to become a leader in commercialization of research. We are very grateful for Mrs. Boucher-Champagne's 8 years of continuous commitment."Michel Bouvier, Chief Executive Officer and Principal Investigator, IRIC (Institute for Research in Immunology and Cancer)

Catherine Bouchard has more than 10 years of experience in healthcare equity research. She is currently Head of Research, Life Sciences at the Caisse de dpt et placement du Qubec, where she has served as Senior Healthcare Analyst since 2012. Prior to joining CDPQ, Ms. Bouchard spent 5 years at Valeurs Mobilires Banque Laurentienne, where she was the Lead Analyst covering healthcare stocks. Her expertise in industry analysis and her deep knowledge of the healthcare sector will be key additions for IRICoR. She holds a B.Sc. in Microbiology and Immunology and an M.Sc. in Biomedical Sciences from Universit de Montral, as well as an MBA from HEC Montreal.

Dr. Godbout and Ms. Bouchard are joining a Board that stands out for its Members' deep commitment, diverse expertise in both health sciences and business matters, as well as its extended network.

About the Institute for Research in Immunology and Cancer Commercialization of Research (IRICoR)

As Universit de Montral's drug discovery and project maturation cluster, IRICoR is a not-for-profit organization based at the Institute for Research in Immunology and Cancer (IRIC), with the mandate to accelerate the discovery, development and commercialization of novel therapies in cancer, immunotherapy and related fields. Since its creation in 2008, IRICoR successfully invests in and supports cutting-edge projects with disruptive potential to rapidly translate innovation into patient-accessible therapies, through either co-development partnerships with industry or company creation. IRICoR seamlessly integrates business-related expertise with industry-level drug discovery in a world-renowned research institute, providing academics with access to a full drug discovery chain with one of the largest academia-based medicinal chemistry groups in Canada. For more information about IRICoR: http://www.iricor.ca

About the Institute for Research in Immunology and Cancer (IRIC)

An ultra-modern research hub and training centre located in the heart of the Universit de Montreal, the Institute for Research in Immunology and Cancer (IRIC) was created in 2003 to shed light on the mechanisms of cancer and discover new, more effective therapies to counter this disease. IRIC operates according to a model that is unique in Canada. Its innovative approach to research has already led to discoveries that will, over the coming years, have a significant impact on the fight against cancer. For further information visit http://www.iric.ca

About the University of Montreal

Deeply rooted in Montreal and dedicated to its international mission, the University of Montreal is one of the top 100 universities in the world. It was founded in 1878, and together with its two affiliated schools, HEC Montral and Polytechnique Montral, constitutes the largest centre of higher education and research in Quebec and one of the major centres in North America. The University of Montreal brings together more than 2,700 professors and researchers and welcomes more than 68,000 students. http://www.umontreal.ca

SOURCE Institut de recherche en immunologie et en cancrologie de l'Universit de Montral

Continue reading here:
IRICoR announces the appointment of Dr. Martin Godbout as Chairman of its Board of Directors and of Ms. Catherine ... - Markets Insider

Physiology-driven genetic changes have positive influence on brain development – News-Medical.net

July 31, 2017

SCIENTISTS in the UK and India have discovered more evidence that positive stimuli in early childhood can benefit the infant brain.

A comparative study of genetic variations between two parts of the brain found evidence for progressive variations in the brain's genome benefiting physiological development.

And they believe such variations may be linked to the level of brain activity determined by so-called 'nurture' factors, which are environmental rather than hereditary.

"The implication is that early life positive experiences can stimulate cognitive activities and will favor such 'beneficial' variations, whereas, negative experiences or lack of cognitive stimulation can reduce the genomic diversity resulting in limiting brain capacity," said Dr Arijit Mukhopadhyay, a researcher in human genetics and genomics at the University of Salford.

It is one of the first studies to show the effect of brain activity on genomic changes, and is published in F1000 Research, Dr. Mukhopadhyay and colleagues from CSIR-Institute of Genomics & Integrative Biology, Delhi.

Dr. Mukhopadhyay explains: "It is generally assumed that as we inherit our genetic blueprint (DNA) from our parents, we also inherit the genetic variations alongside. While this is largely true, this research along with other reports in the recent literature shows that some variations - termed de novo somatic variations - occur as a normal process and are added to diversify our genetic repertoire.

The team collected two different parts of the human brain, frontal cortex and corpus callosum from multiple individuals, postmortem, from the Brain Bank, (the individuals died due to road accidents without any known disease.)

The researchers extracted DNA from the tissue and performed state-of-the-art genomic sequencing to identify genetic variations between the two. The study found a higher number of possibly 'beneficial' variations in the cortex compared to the corpus callosum of the same individuals.

Dr. Mukhopadhyay said: "This finding is an important step in our understanding of early brain development and of how local genetic variations can occur and shape our physiology.

"It is likely that genetic variations beyond those we inherit are important for our ability to adapt and evolve locally for specific organs and tissues.

"We believe our results indicate that such physiology driven genetic changes have a positive influence on the development of the neuronal connectivity early in life."

Excerpt from:
Physiology-driven genetic changes have positive influence on brain development - News-Medical.net

Anatomy and physiology of ageing 7: the endocrine system – Nursing Times

Scroll down to read the article or download a print-friendly PDF here

John Knight is senior lecturer in biomedical science; Yamni Nigam is associate professor in biomedical science; both at the College of Human Healthand Science, Swansea University.

Glands in the endocrine system produce a range of hormones that regulate our bodys activities by keeping substances such as blood glucose and electrolytes within their normal ranges. Like all other body systems, the endocrine system undergoes age-related changes that negatively affect its functioning. As a result of these changes, older people are more prone to disturbed sleep patterns, have a reduced metabolic rate, lose bone density, accumulate body fat, and show increases in blood glucose. As a consequence, they are at higher risk of health issues such as insomnia, fractures, type 2 diabetes and cognitive decline. This seventh article in our series about the effects of age on the body describes what happens, with advancing age, to endocrine glands and hormone production.

Knight J, Nigam Y (2017) Anatomy and physiology of ageing 7:the endocrine system. Nursing Times [online]; 113: 8, 48-51

The endocrine system works in conjunction with the nervous system to regulate, and coordinate the activities of, the bodys tissues and organs. It consists of a collection of glands located in different parts of the body the main ones being the pituitary, pineal, thyroid, parathyroids, adrenals, pancreas, ovaries and testes (Fig 1). These glands produce a variety of blood-borne chemical signals called hormones, which play an essential role in maintaining balance (homoeostasis) in the body, helping to ensure that variables such as blood glucose and electrolytes are kept within normal ranges.

fig 1 the effects of ageing on endocrine function

The pituitary gland, often referred to as the master gland, produces several major hormones and regulates the activity of many other endocrine glands. It is split into a posterior portion, which is formed from neural tissue extending from the hypothalamus, and an anterior portion, which is formed from epithelial cells derived from the roof of the oral cavity.

The anterior pituitary secretes growth hormone (somatotropin), which promotes the growth of bone, muscle and most of the major internal organs. In early childhood, somatotropin is secreted in relatively small amounts, but during the teenage years there is a marked increase in serum somatotropin levels corresponding to the growth spurts of puberty. Around the age of 25-30, somatotropin secretion begins to decline in both men and women. In men it is estimated to halve every seven years although there appears to be much variation between individuals (Gentili, 2015).

The decline in somatotropin secretion in later years is often referred to as the somatopause and is associated with a variety of physiological changes (Jonas et al, 2015; Veldhuis et al, 2005), including:

The somatopause can be hastened in people who lead a sedentary lifestyle and in those who already carry a high percentage of body fat. Conversely, in premeno-pausal women, oestrogen appears to slow its onset and progression (Gentili, 2015).

The exact causes of somatopause are yet to be fully established, however, the age-related decrease in somatotropin secretion mirrors the decrease of growth-hormone releasing hormone (GHRH) secretion by the hypothalamus. Recent research indicates that some of the negative physiological changes that come with declining levels of somatotropin can be reversed by growth hormone replacement therapy. In clinical trials, recombinant human growth hormone has been shown to improve lean muscle mass retention and quality of life scores in older people (Jonas et al, 2015).

The pineal gland is slightly smaller than a pea and resembles a small pine cone hence its name. Found in the diencephalon, towards the centre of the brain, it synthesises the hormone melatonin from the neurotransmitter serotonin. The pineal gland functions like an internal body clock: during the day, when there is a lot of light, melatonin secretion is inhibited, but as the day draws to a close and light diminishes, melatonin secretion increases, preparing the body for sleep.

As we age, the pineal gland undergoes a process of calcification, detectable even in young children. Melatonin levels progressively decrease: 60-year-olds have 80% less melatonin in their blood than teenagers. Some drugs commonly prescribed to older people, such as beta blockers and non-steroidal anti-inflammatory drugs, can reduce melatonin levels even further.

Decreased melatonin levels are linked to an increased prevalence of sleep disturbances and, in some people, may ultimately lead to geriatric insomnia (Bubenik and Konturek, 2011). Since sleep is essential for cognitive function, sleep disturbances can exacerbate age-related changes in the brain.

There is some evidence that exposure to bright light either sunlight or artificial light in the morning increases the speed of sleep onset by triggering an earlier release of melatonin in the evening. Similarly, the therapeutic use of prolonged-release melatonin has been shown to improve sleep onset time, sleep quality, morning alertness and quality of life in people aged 55 and over who have insomnia (Wade et al, 2007)

The thyroid gland plays a major role in controlling metabolism and adjusting blood calcium levels. The hormones it secretes regulate a number of physiological processes, including:

The thyroid secretes the iodine-containing hormones T4 (tetraiodothyronine, which is also known as thyroxine) and T3 (triiodothyronine), which largely control cellular metabolism. T4 is released in greater quantities than T3, the typical ratio being 15:1. T4 is then rapidly converted into the more biologically active T3, which is around three times more potent in terms of increasing the metabolic rate.

The clearance of T4 by the liver decreases with age, but this is offset by a gradual decline in T4 secretion, so T4 serum levels tend to remain constant. However, there is a clear age-related decrease in the levels of serum T3, as well as of thyroid-stimulating hormone (TSH) produced by the pituitary gland (Peeters, 2008; Chahal and Drake, 2007). This may contribute to the gradual reduction in basal metabolism that is apparent in many people in middle and old age (in which the decline in lean muscle mass described above also plays a role).

With advancing age, autoimmune reactions against ones own thyroid gland are commonly seen. Indeed, the presence, in older people, of antibodies specific to thyroid tissue is so common that it is often considered a normal age-related change. A high concentration of such antibodies may herald the onset of autoimmune hypothyroidism, a disease affecting up to 5% of the over-60s and associated with low metabolic rates, a tendency to put on weight and low core temperature. Since this condition is autoimmune in nature, women are at greater risk of developing it (this is true for most autoimmune diseases): up to eight times more women than men experience autoimmune hypothyroidism.

The results of thyroid function tests should be assessed carefully in older people, as common long-term conditions (such as chronic obstructive pulmonary disease, hypertension, diabetes and arthritis) and dieting can lead to reductions in circulating thyroid hormones, particularly the more active T3. This phenomenon of reduced thyroid function in the absence of thyroid disease is referred to as non-thyroidal illness. Similarly, many drugs used to treat long-term conditions in older people (for example, lithium and glucocorticoids) can supress thyroid function or reduce the activity of circulating thyroid hormones, leading to a reduction in metabolic rate (Peeters, 2008).

The thyroid gland also plays a role in calcium homoeostasis. When we consume foods rich in calcium, it releases calcitonin, which inhibits the activity of osteoclasts bone cells that break down bone tissue (bone is a dynamic tissue continually being built and broken down). By inhibiting osteoclast activity, calcitonin indirectly increases bone density.

Few studies have examined the effects of ageing on calcitonin production in humans. The most comprehensive study, dating back to 1980, demonstrated an age-related decline in calcitonin production in 50 healthy women aged between 20 and 69 years (Shamonki et al, 1980). This decline may partially explain the reduction in bone mass seen in most women as they grow older. However, a later study has contradicted these findings, showing that although women appear to have lower levels of calcitonin secretion than men, there is no clear age-related decrease in serum calcitonin concentration (Tiegs et al, 1986).

The posterior portion of the thyroid is the location of four tiny parathyroid glands, which secrete parathyroid hormone (PTH) whenever blood calcium levels fall. Since a normal concentration of calcium is essential to many physiological processes (including muscle contraction, nerve conduction and blood clotting), the reserves of calcium stored in the skeleton need to be mobilised. PTH triggersthe release of calcium from the bonesinto the blood by indirectly stimulating osteoclasts.

Several studies have shown that most people, as they grow older, have significantly increased levels of circulating PTH (Portale et al, 1997). This hyperparathyroidism may well be one of the main causes of the reduction in bone density commonly seen in middle and old age. Recent studies have also shown a potential link with other pathologies, particularly age-related cognitive decline and dementia (Braverman et al, 2009).

The endocrine regions of the pancreas (islets of Langerhans) regulate bloodglucose levels. Beta cells in the islets secrete insulin in response to increased blood glucose for example, after a carbohydrate-rich meal. Insulin binds to receptors present on most cells, triggering the uptake of glucose from the blood. Once inside the cells, glucose is either metabolised immediately to release energy, or stored and converted into glycogen.

Alongside race, genetic predisposition and a high body mass index, ageing is one of the many risk factors linked to the development of type 2 diabetes (Knight and Nigam, 2017). Ageing human cells become less sensitive to the effects of insulin. The most likely cause appears to be a reduction in the number of insulin receptors at the surface of cells. This gradual insulin resistance goes hand in hand with an increase in blood glucose concentrations.

As shown in a study of 6,901 non-diabetic people (Ko et al, 2006), fasting blood glucose levels rise by around 0.15mmol/L for each decade of life after the age of 20. Whether this rise is a normal age-related change or a sign of diabetes in its early stages is not always clear, but it is certainly seen in many older people with no other symptoms of diabetes.

With advancing age, the insulin-producing beta cells become less sensitive to the level of glucose in the blood, so higher blood glucose levels are needed to trigger insulin release. Since older peoples cells are less receptive to insulin, the pancreas often responds by producing more, leading to increased insulin levels in the blood (hyperinsulinaemia). This can put excessive stress on the beta cells, leading to their exhaustion.

Age-related depletion of the beta cell population in the pancreas also occurs as a result of increased programmed cell death (apoptosis) and a diminished ability of the pancreas to produce new cells. Beta cell exhaustion and depletion result in a drop of insulin secretion of up to 0.5% per year of life. Additionally, the clearance of insulin by the liver increases with age, so there is less insulin available to interact with cells and promote glucose uptake.

These age-related changes to insulin production, clearance and response contribute to the creation of a diabetogenic environment. This may partially explain why the risk of developing type 2 diabetes increases with age (Brown, 2012).

The accumulation of abdominal fat is a common feature of ageing, particularly in people who have a poor diet and/or a sedentary lifestyle. Many age-related changes to the endocrine system contribute to this accumulation of adipose tissue, including the somatopause, autoimmune hypothyroidism, insulin resistance, and reduced circulating sex hormones.

This abdominal fat accumulation is linked to heart disease, high blood pressure and type 2 diabetes. These conditions may occur in isolation or together in the form of metabolic syndrome (Gong and Muzumdar, 2012).

The two adrenal glands are located above the kidneys and each consists of two main regions: the adrenal medulla (inner region) and the adrenal cortex (outermost layer).

The adrenal medulla is the location of chomaffin cells, which secrete the catecholamines adrenaline (epinephrine) and noradrenaline (norepinephrine). These are the fight or flight hormones that prepare the body for activity when it is threatened or in a state of excitement. The effects of adrenaline and nor-adrenaline include:

Ageing is associated with a decline in the secretion of adrenaline, but adrenaline plasma levels remain relatively constant

as clearance by the kidneys is usually reduced. There is some evidence that older men secrete less adrenaline in response to acute stress than younger men (Seals and Esler, 2000).

The adrenal cortex synthesises a varietyof steroidal hormones from cholesterol, mainly aldosterone and cortisol.

Aldosterone is a mineralocorticoid that regulates plasma levels of sodium and potassium, and plays an important role in water balance and blood pressure control. Research has revealed an age-related decrease in serum aldosterone levels, effectively reducing the bodys ability to retain sodium.

Decreased aldosterone secretion may contribute to postural hypotension and the light-headedness that is often experienced by older people when they stand up. This is supported by research demonstrating significant reductions in serum aldosterone levels in older people when they are upright, as opposed to recumbent (Hegstad et al, 1983).

Since sodium attracts water into the cardiovascular system via osmosis, lower plasma sodium levels (hyponatraemia) can lead to reduced blood volume and blood pressure. Several medications commonly prescribed to older people such as opiates, non-steroidal anti-inflammatory drugs, diuretics and antidepressants can exacerbate hyponatraemia (Liamis et al, 2008). Blood volume and blood pressure may be further reduced by age-related increases in the secretion of atrial natriuretic hormone (ANH), a powerful diuretic produced by the heart (Miller, 2009).

Cortisol is a glucocorticoid and its release is triggered by biological stressors such as physical injury or starvation. It is a natural anti-inflammatory and plays an important role in the breakdown of protein and fat.

Research into how cortisol levels change with ageing is often contradictory. Initial studies suggested that there could be a 20-50% increase in the mean levels of cortisol secretion between the ages of 20 and 80 (Chahal and Drake, 2007). More recently, however, it has been shown that this is not necessarily true: in some people, cortisol secretion diminishes with age, in others levels remain relatively stable throughout life (Wolf, 2015).

There appears to be a link between increased cortisol levels, reduced bone density and increased risk of bone fracture. There is also growing evidence that a higher cortisol concentration can contribute to the loss of cells from the hippocampus, resulting in hippocampal atrophy. This is often associated with a reduction in cognitive function in older people (Chahal and Drake, 2007). Other studies have shown that age-related increases in cortisol may also be linked to memory loss and sleep disorders (Chahal and Drake, 2007; Wolf et al, 2005).

There is some evidence that exercising regularly and maintaining a low percentage of body fat may slow the onset of the somatopause, help maintain bone density and improve the control of blood glucose. Supplementation with synthetic growth hormone has recently been shown to increase lean muscle mass in older people. However, this kind of therapy is associated with many side-effects such as joint pain, oedema and impaired glucose tolerance (Jonas et al, 2015).

The most famous and most thoroughly researched hormone replacement therapies are those that are used to treat the complications of the menopause. These therapies will be explored in the next article in this series.

Braverman ER et al (2009) Age-related increases in parathyroid hormone may be antecedent to both osteoporosis and dementia. BioMed Central Endocrine Disorders; 9: 21, 1-10.

Brown JE (2012) The ageing pancreas. British Journal of Diabetes and Vascular Disease; 12: 3, 141-145.

Bubenik GA, Konturek SJ (2011) Melatonin and aging: prospects for human treatment Journal of Physiology and Pharmacology; 62: 1, 13-19.

Chahal HS, Drake WM (2007) The endocrine system and ageing. Journal of Pathology; 211: 2, 173-180.

Gentili A (2015) Growth hormone replacement in older men. Medscape.

Gong Z, Muzumdar RH (2012) Pancreatic function, type 2 diabetes, and metabolism in aging. International Journal of Endocrinology; 2012: 320482.

Hegstad R et al (1983) Ageing and aldosterone. American Journal of Medicine; 74: 3, 442-448.

Jonas M et al (2015) Aging and the endocrine system. Postpy Nauk Medycznych; 28: 7, 451-457.

Knight J, Nigam Y (2017) Diabetes management 1: disease types, symptoms and diagnosis. Nursing Times; 113: 4, 40-44.

Ko GT et al (2006) Effects of age on plasma glucose levels in non-diabetic Hong Kong Chinese. Croatian Medical Journal; 47: 5, 709-713.

Liamis G et al (2008) A review of drug-induced hyponatremia. American Journal of Kidney Disease; 52: 1, 144-153.

Miller M (2009) Fluid balance disorders in the elderly. American Society of Nephrology online curricula: geriatric nephrology.

Peeters RP (2008) Thyroid hormones and aging. Hormones; 7: 1, 28-35.

Portale AA et al (1997) Aging alters calcium regulation of serum concentration of parathyroid hormone in healthy men. American Journal of Physiology; 272: 139-146.

Seals DR, Esler MD (2000) Human ageing and the sympathoadrenal system. Journal of Physiology; 528: 3, 407-417.

Shamonki IM et al (1980) Age-related changes of calcitonin secretion in females. Journal of Clinical Endocrinology and Metabolism; 50: 3, 437-439.

Tiegs RD et al (1986) Secretion and metabolism of monomeric human calcitonin: effects of age, sex, and thyroid damage. Journal of Bone and Mineral Research; 4: 339-349.

Veldhuis JD et al (2005) Joint mechanisms of impaired growth-hormone pulse renewal in aging men. Journal of Clinical Endocrinology and Metabolism; 9: 7, 4177-4183.

Wade AG et al (2007) Efficacy of prolonged release melatonin in insomnia patients aged 55-80 years: quality of sleep and next-day alertness outcomes. Current Medical Research and Opinion; 23: 10, 2597-2605.

Wolf OT (2015) Effects of Stress on Memory: Relevance for Human Aging. Encyclopedia of Geropsychology. Singapore: Springer Science.

Wolf OT et al (2005) Subjective memory complaints in aging are associated with elevated cortisol levels. Neurobiology of Aging; 26: 10, 1357-1363.

Read more here:
Anatomy and physiology of ageing 7: the endocrine system - Nursing Times

Researchers describe structures, mechanisms that enable bacteria to resist antibiotics – Phys.Org

A ribbon diagram of the three-part efflux pump of the Campylobacter jejuni bacterium. Credit: Edward Yu/Iowa State University

Two new discoveries from Edward Yu's Iowa State University laboratory are adding to the scientific understanding of how bacteria resist antibiotics.

Yu and his research group have just described two structures and mechanisms - efflux pumps and reinforced cell walls - that certain disease-causing bacteria use to keep antibiotics away. That understanding could one day lead to new treatments that disable the structures and restore the effectiveness of drugs.

"We study a lot of efflux pumps to understand antibiotic resistance," said Yu, an Iowa State professor with appointments in physics and astronomy; chemistry; biochemistry, biophysics and molecular biology; and the U.S. Department of Energy's Ames Laboratory. "Cell wall remodeling is also a major mechanism to work against antibacterial drugs.

"The structure and mechanism depend on the bacteria you're talking about - and the bacteria will find a way."

Two journals have just published the latest findings by Yu's research group:

Previous studies reported the three molecules of the pump worked in a synchronized rotation - one molecule accessing, one molecule binding and one molecule extruding - to pump antibiotics from the cell. Yu's research group found that each part of the pump worked independently of the others, essentially creating three pumps in one structure.

"The three independent pumps make it a more powerful multidrug efflux pump," Yu said.

The paper focuses on how these bacteria transport hopanoid lipid compounds to their outer cell membranes. The compounds contribute to membrane stability and stiffness.

"Overall our data suggest a novel mechanism for hopanoid transport involved in cell wall remodeling, which is critical for mediating multidrug resistance in Burkholderia," the authors wrote in a project summary.

Grants from the National Institutes of Health supported both studies. Grants from the U.S. Department of Energy also supported ultra-bright, high-energy X-ray experiments at the Advanced Photon Source at Argonne National Laboratory in Illinois.

Yu and his research group have a long history of successfully using X-ray crystallography to describe and understand the structure of pumps, transporters and regulators in bacteria. A gallery on his research group's website shows ribbon diagrams of 21 different structures.

Because of Yu's significant contribution to the understanding of antimicrobial resistance in bacteria, the American Academy of Microbiology elected him to be an academy fellow earlier this year.

With that comprehensive understanding of the structures and mechanisms behind bacterial resistance to antibiotics, Yu said his research group is beginning to look at how the pumps and transporters can be turned off.

"We're trying to find an inhibitor compound," Yu said. "We're thinking about doing a little more translational science. We have a lot of rich information about the structure and function of these pumps. Why not use it?"

Explore further: Scientists describe protein pumps that allow bacteria to resist drugs

More information: Chih-Chia Su et al, Structures and transport dynamics of a Campylobacter jejuni multidrug efflux pump, Nature Communications (2017). DOI: 10.1038/s41467-017-00217-z

Nitin Kumar et al. Crystal structures of theBurkholderia multivoranshopanoid transporter HpnN, Proceedings of the National Academy of Sciences (2017). DOI: 10.1073/pnas.1619660114

Continued here:
Researchers describe structures, mechanisms that enable bacteria to resist antibiotics - Phys.Org

Allahabad University scientists create ‘accelerated ageing model’ in … – Hindustan Times

Decoding aging is one complicated process that scientists across globe are busy working on.

While a revolutionary breakthrough is still awaited, a group of scientists from Allahabad have developed unique model of rat which can go a long way in helping them find a formula to control the process.

Perhaps taking a cue from Bollywood blockbuster Paa, the scientists have developed a model of rat which displays a higher rate of aging.

The accelerated aging model of rat provides a great tool for scientists to study aging and also to test anti-aging drugs, claims prof SI Rizvi from the Biochemistry department of Allahabad University (AU).

Rizvi is leading the research team.

The teams findings and achievement have been published in the recent issue of the prestigious research journal Biochemical and Biophysical Research Communications published from US.

Explaining his new research, prof Rizvi said that his team created a rat model which mimics the human condition of Progeria, a disease in which the patient starts to show a faster rate of aging.

Progeria syndrome was highlighted in the acclaimed Hindi movie Paa wherein the character was portrayed effectively by Amitabh Bachchan.

Progeria is a rare genetic condition that causes a childs body to age fast. Most kids with progeria do not live past the age of 13. The disease affects both sexes and all races equally. It affects about 1 in every 4 million births worldwide. Medical experts believe that India has around 8-10 reported cases of progeria and potentially 66 unreported cases.

To study aging, scientists rely on animal models such as C elegans (an earthworm), fruit flies, and mice. The consideration for choosing an animal is primarily based on its lifespan. Shorter lifespan provides an opportunity to study age-dependent changes in a shorter time frame.

To create the Progeria model of rat, the Allahabad University scientists subjected normal rats to chronic treatment of 30 days with dihydrotachysterol, a chemical similar to vitamin D. A look into relevant scientific literature reveals that very few studies have been conducted on such a model of rat.

Normal experimental rats have a lifespan of two years, which is too large a time for conducting experiments. The rat model mimicking Progeria provides a very good model to study aging process in a short span of time, added prof Rizvi.

The young progeria-mimicking rats display a certain level of oxidative stress (an established hallmark of aging) equivalent to old age rats.

The research group will now test Metformin, a common anti-diabetic drug, as an experimental anti-aging drug on increased aging model rats. Initial results using Metformin as an anti aging drug have been very exciting, added prof Rizvi.

See the article here:
Allahabad University scientists create 'accelerated ageing model' in ... - Hindustan Times